2. Academic Validation
  3. Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron

Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron

  • Biochem Pharmacol. 2021 Apr;186:114436. doi: 10.1016/j.bcp.2021.114436.
Sai Ma 1,  Anli Liu 1,  Xiang Hu 2,  Qi Feng 1,  Yanqi Zhang 3,  Nailin Li 4,  Jun Peng 5,  Zi Sheng 6
Affiliations

Affiliations

  • 1 Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • 2 Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Jinan, China.
  • 3 Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • 4 Department of Medicine-Solna, Clinical Epidemiology Unit, Clinical Pharmacology Group, Karolinska Institute, Stockholm, Sweden.
  • 5 Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. Electronic address: junpeng88@sina.com.cn.
  • 6 Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; School of Medicine, Cheeloo College of Medicine, Shandong University, Jinan, China. Electronic address: zisheng92@email.sdu.edu.cn.
PMID: 33539815 DOI: 10.1016/j.bcp.2021.114436
Abstract

Thrombocytopenia is common among patients with viral hepatitis, limiting the use of Antiviral therapy. Eltrombopag (EP) is a Thrombopoietin Receptor (TPO-R) agonist that has been approved for treatment of immune thrombocytopenia patients with hepatitis virus Infection. Interferon-α (IFN-α) plays a crucial role in the Antiviral response, and is recommended as the first-line agent for chronic hepatitis B patients. Here, we investigated whether EP inhibits the production of IFN-stimulated genes (ISGs) induced by IFN-α through the TPO-R-independent pathway by mediating Reactive Oxygen Species production by iron chelation. Our results assessed the inhibitory effect of EP on IFN-α signaling, which contributes to the downregulation of ISGs produced by monocytes and sheds light on the underlying mechanisms using iron chelation to treat patients with hepatitis-related immunological thrombocytopenia.

Keywords

Eltrombopag; IFN-stimulated gene; Interferon-α; Iron chelation; Reactive oxygen species; Thrombocytopenia; Viral hepatitis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z